Alamar Biosciences Prices IPO at $17, Opens at $22.60 with $1.5B Valuation
Alamar Biosciences debuted on NASDAQ on April 17, 2026, pricing its shares at $17 and opening at $22.60, giving it a market cap of about $1.5 billion. Its ARGO™ HT automated proteomics system has over 100 instruments installed across 25 countries, serving 300 customers.
1. NASDAQ Listing and Valuation
Alamar Biosciences successfully listed on NASDAQ on April 17, 2026, issuing shares at $17 and opening at $22.60, reflecting a roughly 33% debut gain and a market capitalization near $1.5 billion.
2. Institutional Ownership and Funding History
Qiming Venture Partners led Alamar’s Series A financing in 2020 and continued support through Series B and C rounds, entering the IPO with a 19.2% stake as one of the largest institutional investors.
3. Proteomics Platform and Global Adoption
Alamar’s self-developed NULISA™ technology offers ultra-high sensitivity and broad dynamic range, while its ARGO™ HT system supports a seamless automated workflow; by end-2025, over 100 instruments were installed across 25 countries, serving more than 300 customers and underpinning over 100 scientific publications.